Novosom granted US and European patents for RNAi-delivering Smarticles
Novosom AG announced that it has been granted patents for both the USA and Europe for its drug delivery technology Smarticles®. Smarticles® are fully charge reversible liposomes for the in vivo drug delivery of nucleotides like siRNA or antisense to targeted cells.
The US patent is entitled "Amphoteric liposomes and their use" and the US patent number is US 7371404. At the same time, the European Patent Office granted patent number EP 1363601 with the same title.
Elias Papatheodorou, CEO of Novosom, said, "We are delighted to be granted these US and European patents for our world-class RNAi and siRNA drug delivery sytem Smarticles®. In addition to the patents already granted Novosom, this forms a part of the strong intellectual property position Novosom is building in the growing field of nucleic-acid drugs based on RNA interference."
In March, ProNAi, a collaboration partner of Novosom announced the successful completion of the IND for the drug candidate PNT2258 which uses the Smarticle® delivery technology for a novel class of oligonucleotide therapeutics against multiple cancer types.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.